ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
about
Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 PathwaysSuperbinder SH2 domains act as antagonists of cell signalingFGF receptors: cancer biology and therapeuticsInduction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer3D super-resolution imaging with blinking quantum dots.Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells.Epidermal growth factor receptor activity is necessary for mouse basal cell proliferationMitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays.CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical CancerPrognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers.HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cellsInherited and acquired alterations in development of breast cancer.Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation.Feasibility of multiplex quantum dot stain using primary antibodies from four distinct host animals.Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indicationsSomatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.Emerging EGFR antagonists for breast cancer.Targeting CDKN3 in cervical cancer.Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.A comparative survey of functional footprints of EGFR pathway mutations in human cancers.Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia.Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines.Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.Isolation and identification of three new chromones from the leaves of Pimenta dioica with cytotoxic, oestrogenic and anti-oestrogenic effects.
P2860
Q27315022-1C664E92-68A9-4E4D-B750-7DC4A005354FQ27682496-32775A5E-259C-4517-8F77-E49B6F1DF9B3Q28291186-D0C3EE50-51C5-4779-80D2-086418A25E5FQ28534358-64C80CBD-CE16-48E9-8622-560868C2BCF6Q30560943-B97C7EED-9886-4784-8740-2110732C1145Q31073908-A4FB8BD6-3C9A-4CFC-BD8A-21D95746E1C0Q34519360-742968A6-95BC-4799-9E40-091AA1639CC9Q34584632-5593C557-DC25-4070-B049-DB300D10DAF4Q35487994-607BED26-E9BA-41AF-A570-85E9B05C224FQ35776083-CAD2506C-D95C-4097-A9CF-C989445C2C0BQ35879733-1DEEE365-7D4E-482B-899C-8C8BBE5C3D27Q36533669-F0299071-D58E-4489-BAF1-9883F20EF819Q36766067-B0E88528-23D3-40FF-AC8A-E2D14D71F1EFQ36870104-3BE51687-6045-459E-9CF0-BA2F6E026519Q36925229-DDF8E7FF-7CEB-4D85-8843-F400051EF813Q37033459-DC4F79FA-3A04-445D-BDB3-B050FE8465FBQ37172258-DC8EB079-0E29-44D4-BF33-08C14FC72DE4Q37607746-8984F569-1261-4340-AE00-93092EF03429Q37687527-E03E5237-AC4F-4CAE-8556-4CA7189979CBQ38211951-41411D7E-1D42-4C1B-940D-B3E8376B02EEQ38242742-F3E1E246-6322-47B6-B7DA-D8C5BE88600EQ39064114-C1A39B61-014E-4856-8762-A2DDCAE583D3Q39069318-CB5D9A2C-4BE4-4FB2-A92E-E83644B18095Q39129968-BAF0F35B-C706-431B-9FCF-8AD87853BE80Q39459376-46BDEFD3-264F-4B0D-A24B-DD73FCC9F6F3Q42370727-47E7544B-D9CC-4C46-857A-101AC872BE40Q45905776-954EA30C-B6C8-45D6-BABE-6AA494FA2114Q50419857-6CD4F7D6-2AE8-4D75-8947-3E75C4109885Q51734194-1A74EAAA-C5B2-4A31-B4C9-AF7B8B4C4B8BQ52643130-2C601CFD-EAD5-45F9-9EBB-D661C03EA96C
P2860
ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ErbB family receptor inhibitor ...... d future clinical perspective.
@en
ErbB family receptor inhibitor ...... d future clinical perspective.
@nl
type
label
ErbB family receptor inhibitor ...... d future clinical perspective.
@en
ErbB family receptor inhibitor ...... d future clinical perspective.
@nl
prefLabel
ErbB family receptor inhibitor ...... d future clinical perspective.
@en
ErbB family receptor inhibitor ...... d future clinical perspective.
@nl
P2860
P356
P1476
ErbB family receptor inhibitor ...... d future clinical perspective.
@en
P2093
Anila Dwivedi
Ruchi Saxena
P2860
P304
P356
10.1002/MED.20209
P577
2010-10-25T00:00:00Z